ANVISA approval for CuraTeQ Biologics biosimilars facility in Hyderabad

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.2%Reaction day

₹1583.70

prior close

₹1564.00

announcement price

After-mkt

timing

Nifty Midcap 150market-1.1%-2.2% vs market

Pharmaceuticals peers, median of 165sector-1.6%-1.7% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Midcap 150 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.5

15m

-1.7

30m

-1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.2-1.1-2.2-1.6-1.7

Next day

-3.7-2.0-1.6-2.4-1.3

-3.2-2.1-1.1-2.4-0.8

-2.1-1.0-1.0-1.3-0.8

-1.7-1.0-0.7-2.5+0.8

+0.2-0.2+0.4-1.9+2.1

-0.2-0.1-0.1-2.1+1.9

15d

+5.0+1.5+3.5-0.3+5.3

+1.6+1.1+0.5-1.1+2.8

+7.2-1.7+8.8+0.8+6.3

+1.7-9.2+11.0-6.6+8.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics received approval from Brazil's health regulator ANVISA for its Hyderabad biosimilars manufacturing facility. The facility cleared a GMP inspection in May 2026 covering four biosimilar products, drug substance and sterile drug product manufacturing, prefilled syringe and vial filling, packaging, and QC labs. The site is already EMA and WHO certified. The approval allows the company to supply biosimilars to Brazil and other Latin American markets.

Likely market impact

Positively positions Aurobindo's biosimilars arm CuraTeQ to tap the Brazilian and wider Latin American market, supporting future revenue growth.